research use only

Levothyroxine (L-Thyroxine) sodium THR agonist

Cat.No.S3747

Levothyroxine (L-Thyroxine) sodium is the major hormone derived from the thyroid gland. It is the agonist of Thyroid hormone receptor alpha and beta.
Levothyroxine (L-Thyroxine) sodium THR agonist Chemical Structure

Chemical Structure

Molecular Weight: 798.85

Quality Control

Chemical Information, Storage & Stability

Molecular Weight 798.85 Formula

C15H10I4NO4.Na

Storage (From the date of receipt)
CAS No. 55-03-8 Download SDF Storage of Stock Solutions

Solubility

In vitro
Batch:

DMSO : 100 mg/mL ( (125.17 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

In vitro
Levothyroxine can upregulate the expression of P-gp mRNA and protein in LS180 cells and can produce the same effect in Caco-2 cells, which are relatively lacking in PXR. It doea not affect the expression of CYP3A4 in either cell line[1].
In vivo
Levothyroxine is a synthetic T4 hormone that is biochemically and physiologically indistinguishable from the natural one, and it is administered when the body is deficient in the natural hormone. Its nain site of absorption is small intestine, more specifically through the duodenum, jejunum and ileum. Very little is absorbed in the stomach. The bioavailability is about 70-80 % in euthyroid person and may be slightly higher in hyperthyroid patients. The absorption of levothyroxine appears to be influenced by gastric pH. Tmax=2-3 hours and the half-time T1/2 is 6.2 and 7.5 days in euthyroid and hypothyroid patients, respectively[3]. T4 hormones is known to modulate the expression of ionic channels, pumps and regulatory contractile proteins. T4-treatment induces a dose-dependent increase in the duration of contractions. Abnormal uterine contractile pattern are induced by T4-treatment[2].
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04037748 Completed
Healthy
Merck Healthcare KGaA Darmstadt Germany an affiliate of Merck KGaA Darmstadt Germany
June 25 2019 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.